Literature DB >> 26178385

Profiling Humoral Immune Responses to Clostridium difficile-Specific Antigens by Protein Microarray Analysis.

Ola H Negm1, Mohamed R Hamed1, Elizabeth M Dilnot2, Clifford C Shone3, Izabela Marszalowska4, Mark Lynch4, Christine E Loscher4, Laura J Edwards5, Patrick J Tighe2, Mark H Wilcox6, Tanya M Monaghan7.   

Abstract

Clostridium difficile is an anaerobic, Gram-positive, and spore-forming bacterium that is the leading worldwide infective cause of hospital-acquired and antibiotic-associated diarrhea. Several studies have reported associations between humoral immunity and the clinical course of C. difficile infection (CDI). Host humoral immune responses are determined using conventional enzyme-linked immunosorbent assay (ELISA) techniques. Herein, we report the first use of a novel protein microarray assay to determine systemic IgG antibody responses against a panel of highly purified C. difficile-specific antigens, including native toxins A and B (TcdA and TcdB, respectively), recombinant fragments of toxins A and B (TxA4 and TxB4, respectively), ribotype-specific surface layer proteins (SLPs; 001, 002, 027), and control proteins (tetanus toxoid and Candida albicans). Microarrays were probed with sera from a total of 327 individuals with CDI, cystic fibrosis without diarrhea, and healthy controls. For all antigens, precision profiles demonstrated <10% coefficient of variation (CV). Significant correlation was observed between microarray and ELISA in the quantification of antitoxin A and antitoxin B IgG. These results indicate that microarray is a suitable assay for defining humoral immune responses to C. difficile protein antigens and may have potential advantages in throughput, convenience, and cost.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26178385      PMCID: PMC4550668          DOI: 10.1128/CVI.00190-15

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  36 in total

1.  Asymptomatic carriage of Clostridium difficile in patients with cystic fibrosis.

Authors:  S L Peach; S P Borriello; H Gaya; F E Barclay; A R Welch
Journal:  J Clin Pathol       Date:  1986-09       Impact factor: 3.411

Review 2.  Recent advances in Clostridium difficile-associated disease.

Authors:  T Monaghan; T Boswell; Y R Mahida
Journal:  Gut       Date:  2008-02-05       Impact factor: 23.059

3.  Mass-sensing, multianalyte microarray immunoassay with imaging detection.

Authors:  J W Silzel; B Cercek; C Dodson; T Tsay; R J Obremski
Journal:  Clin Chem       Date:  1998-09       Impact factor: 8.327

4.  Profiling the humoral immune response to infection by using proteome microarrays: high-throughput vaccine and diagnostic antigen discovery.

Authors:  D Huw Davies; Xiaowu Liang; Jenny E Hernandez; Arlo Randall; Siddiqua Hirst; Yunxiang Mu; Kimberly M Romero; Toai T Nguyen; Mina Kalantari-Dehaghi; Shane Crotty; Pierre Baldi; Luis P Villarreal; Philip L Felgner
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-12       Impact factor: 11.205

5.  Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection.

Authors:  M Warny; J P Vaerman; V Avesani; M Delmée
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

6.  Immunoglobulin G directed against toxins A and B of Clostridium difficile in the general population and patients with antibiotic-associated diarrhea.

Authors:  A E Bacon; R Fekety
Journal:  Diagn Microbiol Infect Dis       Date:  1994-04       Impact factor: 2.803

7.  Systemic antibody response to Clostridium difficile in colonized patients with and without symptoms and matched controls.

Authors:  Karla Sánchez-Hurtado; Maria Corretge; Esvet Mutlu; Rowan McIlhagger; John M Starr; Ian R Poxton
Journal:  J Med Microbiol       Date:  2008-06       Impact factor: 2.472

8.  Profiling humoral immune responses to P. falciparum infection with protein microarrays.

Authors:  Denise L Doolan; Yunxiang Mu; Berkay Unal; Suman Sundaresh; Siddiqua Hirst; Conrad Valdez; Arlo Randall; Douglas Molina; Xiaowu Liang; Daniel A Freilich; J Aggrey Oloo; Peter L Blair; Joao C Aguiar; Pierre Baldi; D Huw Davies; Philip L Felgner
Journal:  Proteomics       Date:  2008-11       Impact factor: 3.984

9.  Profiling the humoral immune response to Borrelia burgdorferi infection with protein microarrays.

Authors:  Yun Xu; John F Bruno; Benjamin J Luft
Journal:  Microb Pathog       Date:  2008-10-11       Impact factor: 3.738

10.  Clostridium difficile in patients with cystic fibrosis.

Authors:  C J Welkon; S S Long; C M Thompson; P H Gilligan
Journal:  Am J Dis Child       Date:  1985-08
View more
  5 in total

1.  A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection.

Authors:  Ola H Negm; Mohamed Hamed; Tanya M Monaghan
Journal:  J Vis Exp       Date:  2018-06-15       Impact factor: 1.355

2.  A Multi-Factorial Observational Study on Sequential Fecal Microbiota Transplant in Patients with Medically Refractory Clostridioides difficile Infection.

Authors:  Tanya M Monaghan; Niharika A Duggal; Elisa Rosati; Ruth Griffin; Jamie Hughes; Brandi Roach; David Y Yang; Christopher Wang; Karen Wong; Lynora Saxinger; Maja Pučić-Baković; Frano Vučković; Filip Klicek; Gordan Lauc; Paddy Tighe; Benjamin H Mullish; Jesus Miguens Blanco; Julie A K McDonald; Julian R Marchesi; Ning Xue; Tania Dottorini; Animesh Acharjee; Andre Franke; Yingrui Li; Gane Ka-Shu Wong; Christos Polytarchou; Tung On Yau; Niki Christodoulou; Maria Hatziapostolou; Minkun Wang; Lindsey A Russell; Dina H Kao
Journal:  Cells       Date:  2021-11-19       Impact factor: 6.600

3.  Protective antibodies against Clostridium difficile are present in intravenous immunoglobulin and are retained in humans following its administration.

Authors:  O H Negm; B MacKenzie; M R Hamed; O A J Ahmad; C C Shone; D P Humphreys; K Ravi Acharya; C E Loscher; I Marszalowska; M Lynch; M H Wilcox; T M Monaghan
Journal:  Clin Exp Immunol       Date:  2017-03-16       Impact factor: 4.330

Review 4.  Targeting Clostridium difficile Surface Components to Develop Immunotherapeutic Strategies Against Clostridium difficile Infection.

Authors:  Séverine Péchiné; Jean F Bruxelle; Claire Janoir; Anne Collignon
Journal:  Front Microbiol       Date:  2018-05-23       Impact factor: 5.640

5.  High prevalence of subclass-specific binding and neutralizing antibodies against Clostridium difficile toxins in adult cystic fibrosis sera: possible mode of immunoprotection against symptomatic C. difficile infection.

Authors:  Tanya M Monaghan; Ola H Negm; Brendon MacKenzie; Mohamed R Hamed; Clifford C Shone; David P Humphreys; K Ravi Acharya; Mark H Wilcox
Journal:  Clin Exp Gastroenterol       Date:  2017-07-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.